aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 3.76 USD -2.08% Market Closed
Market Cap: 315.6m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+36%
Revenue
Forecast
+21%
Operating Income
Forecast
N/A
Net Income
Forecast
+16%

Wall Street
Price Targets

ATYR Price Targets Summary
aTyr Pharma Inc

Wall Street analysts forecast ATYR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATYR is 19.06 USD with a low forecast of 9.09 USD and a high forecast of 36.75 USD.

ATYR Lowest Forecast
Wall Street Target
9.09 USD
142% Upside
ATYR Average Forecast
Wall Street Target
19.06 USD
407% Upside
ATYR Highest Forecast
Wall Street Target
36.75 USD
877% Upside
Lowest
Price Target
9.09 USD
142% Upside
Average
Price Target
19.06 USD
407% Upside
Highest
Price Target
36.75 USD
877% Upside
aTyr Pharma Inc Competitors:
Price Targets
RCUS
Arcus Biosciences Inc
266% Upside
CDMO
Avid Bioservices Inc
2% Upside
CUV
Clinuvel Pharmaceuticals Ltd
123% Upside
ZYME
Zymeworks Inc
77% Upside
RCUS
Arcus Biosciences Inc
266% Upside
CDMO
Avid Bioservices Inc
2% Upside
CUV
Clinuvel Pharmaceuticals Ltd
123% Upside
ZYME
Zymeworks Inc
77% Upside
A
ARMP
Armata Pharmaceuticals Inc
255% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
20% Upside
EXEL
Exelixis Inc
2% Upside
XOMA
XOMA Corp
285% Upside

Revenue
Forecast

Revenue Estimate
aTyr Pharma Inc

The compound annual growth rate of aTyr Pharma Inc's revenue for the next 4 years is 365%.

N/A
Past Growth
365%
Estimated Growth
Estimates Accuracy
8%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
aTyr Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
aTyr Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-96%
Average Miss
What are analyst estimates?

See Also

Summary
ATYR intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATYR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATYR stock valuation using valuation multiples.
Wall Street Estimates
ATYR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATYR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATYR's stock price target?
Price Target
19.06 USD

According to Wall Street analysts, the average 1-year price target for ATYR is 19.06 USD with a low forecast of 9.09 USD and a high forecast of 36.75 USD.

What is aTyr Pharma Inc's Revenue forecast?
Projected CAGR
365%

The compound annual growth rate of aTyr Pharma Inc's revenue for the next 4 years is 365%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.